Newsquawk Logo

Novartis (NOVN SW) Q1 2026 (USD): Core EPS 1.99 (exp. 2.11), Revenue 13.1bln (exp. 13.6bln), Adj. Op. Income 4.9bln (exp. 5.09bln), reaffirms 2026 guidance

Novartis reported Q1 2026 results that missed expectations on core EPS, revenue, and adjusted operating income, indicating potential challenges in the near term.

Newsquawk StaffPublished On the live feed at , 20 minutes before this page
Newsquawk headlinesUTC

Newsquawk Daily European Opening News - 28th April 2026

Indonesia's Economy Minister says they are going to cut the import duty for naphtha to 0%

Novartis (NOVN SW) Q1 2026 (USD): Core EPS 1.99 (exp. 2.11), Revenue 13.1bln (exp. 13.6bln), Adj. Op. Income 4.9bln (exp. 5.09bln), reaffirms 2026 guidance

Google (GOOGL) has signed a deal with the US Department of Defence allowing the Pentagon to use Google's AI models on classified work, The Information reports citing sources

Heathrow's plans for a third runway is facing growing political uncertainty if Chancellor Reeves is removed after the May elections, FT reports citing sources

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
  • Net sales expected to grow low single-digit and core operating income expected to decline low single-digit

CEO:

  • "With the momentum we are seeing across the business, we remain on track to deliver our full year guidance and look forward to multiple readouts in the second half that could raise our mid- to long-term growth outlook.”

By drug:

  • Strong growth across key drivers led by Kisqali and Pluvicto, partially offset by declines in Cosentyx and Zolgensma. (Novartis)
  • Kisqali 1.516bln (prev. +55% Y/Y).
  • Pluvicto 642mln (prev. +70% Y/Y).
  • Kesimpta 1.164bln (prev. +26% Y/Y).
  • Leqvio 452mln (prev. +69% Y/Y).
  • Scemblix 433mln (prev. +79% Y/Y).
  • Fabhalta 169mln (prev. +103% Y/Y).
  • Rhapsody 37mln.
  • Cosentyx 1.566bln (prev. -2% Y/Y).
  • Zolgensma 302mln (prev. -12% Y/Y).
Context

However, the reaffirmation of full-year guidance and the mention of strong growth drivers like Kisqali and Pluvicto suggest confidence in longer-term prospects, particularly with anticipated drug readouts later in the year that could enhance growth outlooks.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.